Amneal Pharmaceuticals Inc (NYSE:AMRX) – Research analysts at Piper Jaffray Companies lifted their Q3 2019 earnings per share (EPS) estimates for Amneal Pharmaceuticals in a report released on Wednesday, November 7th. Piper Jaffray Companies analyst D. Amsellem now forecasts that the company will earn $0.31 per share for the quarter, up from their previous estimate of $0.30.
A number of other brokerages have also issued reports on AMRX. Cantor Fitzgerald restated a “buy” rating and set a $35.00 target price on shares of Amneal Pharmaceuticals in a research report on Thursday, August 9th. Canaccord Genuity restated a “hold” rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research report on Tuesday, September 4th. Zacks Investment Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Saturday, July 14th. BMO Capital Markets raised their target price on shares of Amneal Pharmaceuticals from $19.00 to $20.00 and gave the stock a “market perform” rating in a research report on Friday, August 10th. Finally, ValuEngine lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 27th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $22.75.
Shares of AMRX opened at $19.75 on Friday. The company has a debt-to-equity ratio of 2.92, a quick ratio of 1.25 and a current ratio of 1.91. The company has a market cap of $5.99 billion, a PE ratio of 31.86, a price-to-earnings-growth ratio of 0.98 and a beta of 1.56. Amneal Pharmaceuticals has a 12-month low of $13.47 and a 12-month high of $24.48.
Amneal Pharmaceuticals (NYSE:AMRX) last announced its earnings results on Wednesday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $476.50 million for the quarter, compared to analyst estimates of $486.01 million. Amneal Pharmaceuticals had a negative net margin of 36.54% and a positive return on equity of 4.98%. The firm’s revenue for the quarter was up 87.1% on a year-over-year basis.
Hedge funds and other institutional investors have recently modified their holdings of the business. DekaBank Deutsche Girozentrale purchased a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth $101,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth $116,000. SG Americas Securities LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth $120,000. Neuburgh Advisers LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth $123,000. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth $130,000. Institutional investors own 31.84% of the company’s stock.
In related news, SVP Nikita Shah sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $23.46, for a total value of $1,173,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Bryan M. Reasons sold 11,698 shares of Amneal Pharmaceuticals stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $23.65, for a total transaction of $276,657.70. The disclosure for this sale can be found here. Company insiders own 3.20% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Article: Why do corrections happen?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.